Tesamorelin 10 mg

Tesamorelin is a synthetic 44-residue research peptide engineered as a stabilized analog of human growth hormone–releasing hormone (GHRH(1-44)). It carries a trans-3-hexenoyl moiety on the N-terminal tyrosine, a modification that confers resistance to dipeptidyl peptidase-IV cleavage and extends plasma residency in laboratory species. It is supplied as an investigational laboratory peptide for use in GHRH-receptor signaling research, somatotropic-axis research, and structure–activity studies on stabilized GHRH analogs.

Laboratory research studies have positioned tesamorelin as a reference compound for examining how N-terminally modified GHRH analogs engage the GHRH receptor on pituitary somatotroph cells. Research models have investigated its receptor binding kinetics, enzymatic stability profile, and downstream pulsatile growth hormone responses, providing comparative data versus native GHRH(1-44) and other secretagogue research peptides (Ferdinandi et al., 2007, Basic & Clinical Pharmacology & Toxicology).

Beyond receptor pharmacology, tesamorelin is investigated in cellular and animal research models that explore somatotropic-axis signal transduction, pituitary research, hepatic lipid-metabolism research, and downstream IGF-1 pathway dynamics. The molecule's trans-3-hexenoyl modification, which enables resistance to enzymatic deactivation and supports extended plasma residency in research models, is also a frequent subject of pharmacokinetics and structural-stability research.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

Growth hormone–releasing hormone (GHRH) is a 44-residue hypothalamic peptide that engages the GHRH receptor on pituitary somatotroph cells and participates in somatotropic-axis research. Native GHRH(1-44) is rapidly inactivated in plasma by dipeptidyl peptidase-IV, which cleaves the N-terminal Tyr-Ala dipeptide and limits its utility as a research reference compound. The development of stabilized GHRH analogs was driven by interest in molecules that preserve receptor engagement while resisting enzymatic deactivation.

Tesamorelin was developed as a synthetic GHRH(1-44) analog with a trans-3-hexenoyl moiety attached to the N-terminal tyrosine. This minimal modification confers resistance to dipeptidyl peptidase-IV cleavage while preserving the native amino acid sequence and receptor-binding pharmacophore, enabling extended plasma residency in laboratory research studies.

This structural design has made tesamorelin a widely studied reference compound for laboratory investigations of GHRH-receptor signaling, somatotropic-axis pulsatility, and downstream IGF-1 pathway dynamics. Research interest spans pituitary research models, hepatic lipid-metabolism research, adipose-tissue research models, and comparative pharmacology with other GHRH analogs and growth-hormone-releasing secretagogues.

1. GHRH-Receptor Engagement

Tesamorelin interacts with the GHRH receptor, a class B G-protein-coupled receptor expressed on pituitary somatotroph cells. Research models indicate that this engagement modulates Gαs-coupled signaling at the GHRH receptor, producing intracellular responses that are comparable to native GHRH(1-44) in laboratory side-by-side studies.

2. Modulation of Cyclic AMP and Pulsatile Growth Hormone Release

Upon receptor binding, tesamorelin engages adenylyl cyclase activity and modulates intracellular cyclic AMP accumulation in somatotroph research models. Downstream, this is associated with protein kinase A activation and pulsatile release of growth hormone from pituitary storage granules, both of which are extensively studied in somatotropic-axis research.

3. Resistance to Dipeptidyl Peptidase-IV

Laboratory research studies have characterized tesamorelin's trans-3-hexenoyl modification as conferring resistance to dipeptidyl peptidase-IV cleavage at the N-terminal Tyr-Ala dipeptide. This enzymatic stability is an active area of structure–activity research and is investigated as a contributor to extended plasma residency in research models relative to native GHRH(1-44).

4. Downstream IGF-1 Pathway Dynamics

Pulsatile growth hormone release in research models engages hepatic growth hormone receptors and modulates insulin-like growth factor-1 (IGF-1) gene expression and secretion. This downstream signaling cascade is investigated in lipid-metabolism research, hepatic-pathway research, and comparative pharmacology research with other somatotropic-axis modulators.

Research Applications

Conclusion

Tesamorelin represents a structurally engineered stabilized GHRH(1-44) analog that has become a central reference compound in GHRH-receptor signaling research. Its combination of preserved native sequence, N-terminal trans-3-hexenoyl modification, and resistance to dipeptidyl peptidase-IV cleavage makes it a valuable investigational laboratory peptide for studying class B G-protein-coupled receptor pharmacology and somatotropic-axis research models.

Research Use Disclaimer

This product is intended for research and laboratory use only. It is designed exclusively for in vitro research purposes. All information provided is for educational and research reference only. This product is not intended for human or animal use. It is not a drug, food, or cosmetic and must not be marketed, labeled, or used as such. Use and handling are restricted to trained and qualified professionals.